Table 2.
Combination therapeutics used in malignancies.
| Combination forms | Combination therapeutics | Associated cancer | Advantages | Reference |
|---|---|---|---|---|
| DNMTi+HDACi | azacytidine + vorinostat | MDS; CMML | more effective than monotherapy | [116] |
| azacytidine + entinostat | CRC | improved antitumor activity | [117] | |
| Epi-drug + targeted drug | ACY-1215 + bortezomib | MM | delayed tumor growth; prolonged survival | [121] |
| TSA + palladium nanoparticles | cervical cancer | increased the potential for successful treatment | [122] | |
| JQ1 + γ-secretase inhibitors | T-ALL | countered the resistance of γ-secretase inhibitors | [123] | |
| Epi-drug + immunomodulators | Panobinostat + bortezomib+dexamethasone | MM | improved progression-free survival | [126] |
| PD-1 blockers +Decitabine | CRC | inhibited tumor growth; prolonged survival | [127] | |
| Azacytidine+pembrolizumab | MDS | safe with controllable toxicity | [128] |
CMML chronic myelomonocytic leukemia, CRC colorectal carcinoma, MDS myelodysplastic syndromes, MM multiple myeloma, T-ALL T-cell acute lymphoblastic leukemia.